BIA 9-1067

Efficacy and Safety of Opicapone in Clinical Practice

The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics

Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects

Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients

Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067

Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers

Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon

Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation

Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide

Effect of BIA 9-1067 on Rasagiline Pharmacokinetics

Effect of Rasagiline on BIA 9-1067 Pharmacokinetics

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa

Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide